Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
$19.58
-$0.64(-3.70%)
At close: 4:00 PM EST
$19.58
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$14.14 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)122.87K
Market Cap
$233.61M
Enterprise Value$186.33M
Total Cash (Recent Filing)$32.44M
Total Debt (Recent Filing)$8.07M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 18, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding12,821,433
10 Day Avg. Volume83,310
30 Day Avg. Volume122,866
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue9.38
Enterprise Value/Gross Profit50.91
Enterprise Value/Ebitda-6.08
Forecast
1Y Price Target
$30.00Price Target Upside53.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Funding And PartnershipsEfforts led by MediWound's U.S. Partner, Vericel, to secure BARDA's recently issued Request for Proposal could increase procurement revenues and provide funding for a US manufacturing facility for NexoBrid.
Market OpportunityEscharEx is being developed for enzymatic debridement of chronic wounds in the outpatient setting, representing a potential ~$2.5B market opportunity.
Regulatory ApprovalsThe expanded manufacturing facility for NexoBrid is expected to reach full operational capacity by YE25, supporting further regulatory approvals.
Bears Say
Financial PerformanceThe Q2 operating loss was $5.7M, and the net loss was $13.3M, or $1.23 per share, which was hurt by $6.6M in non-cash expenses tied to the revaluation of warrants.
Manufacturing CapacityGlobal demand for NexoBrid continues to exceed MDWD's manufacturing capacity, a dynamic that should ease as manufacturing capacity ramps.
Revenue ProjectionsMDWD's revenue projections for 2026 and 2027 were slightly reduced, stemming from refinements to expected manufacturing capacity.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.14 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $233.61M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Nov 18, 2025 which is in 32 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 14, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$0.572 by -$0.658.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.81.
How many shares outstanding does Mediwound have?
Mediwound has 12,821,433 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$1.23 in its last earnings report, missing expectations of -$0.572. Following the earnings report the stock price went down -0.96%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (53.22% Upside)
$30.00 (53.22% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.35%
12-Months-Change
Fundamentals
Return on Equity
-148.65%
Trailing 12-Months
Asset Growth
16.94%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
MediWound's earnings call presented both significant progress and challenges. Highlights included strong progress in clinical trials, partnerships, and revenue growth in the U.S. market for NexoBrid. However, the company faced increased net loss and higher expenses affecting financial performance. Despite these challenges, strategic advancements and collaborations position MediWound for future growth.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(53.22% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
Ventyx Biosciences
―
Tevogen Bio Holdings
―
Ownership Overview
―
Insiders
2.36% Mutual Funds
25.18% Other Institutional Investors
68.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---